ACAD (ACADIA Corp) Multiplikator Forward P/S
Daybue sales and a stable neurological portfolio generate strong cash flow, which drives the dynamics of the ACADIA Pharmaceuticals (ACAD) forward P/S chart. The value 5.30 indicates the status of the current valuation. Absolute pricing power in the rare pathology market guarantees stability, while the development of Parkinson's disease treatments minimizes risks, providing resources for new scientific research.
Ringkesan rincian data analitis ACADIA Corp (ACAD)
- rega pasar lan target rega analis:
- indikator valuasi pasar bisnis:
- statistik nilai buku emiten:
- informasi babagan utang lan solvabilitas:
Utang marang Ekuitas ACADIA Pharmaceuticals|ACAD - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal ACADIA Pharmaceuticals|ACAD - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku ACADIA Corp|ACAD - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan ACADIA Pharmaceuticals|Indikator likuiditas cepet acadia-pharm.com
- rincian asil keuangan lan kelipatan valuasi:
ACAD - Bathi resik|Bathi mangsa ngarep ACADIA Pharmaceuticals|ACAD - Rasio rega pasar marang bathi resik|Pangali Forward P/E ACADIA Pharmaceuticals Inc|ACAD - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA ACADIA Corp|ACAD - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) ACADIA Pharmaceuticals|ACAD - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan acadia-pharm.com|ACAD - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep ACADIA Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:ACADIA Pharmaceuticals Inc. ACAD
To decouple the fundamental value of ACADIA Pharmaceuticals (ACAD) from market speculation, it is critical to evaluate the expected price-to-sales ratio, which compares current market capitalization with projected sales volumes. The stability of this metric is supported by the absence of production downtime due to the contract model and hub automation, which minimizes the risk of multiple inflation and confirms the business's resilience to operational shocks.
Pesaing ACADIA Pharmaceuticals (ACAD)
Rasio rega marang prakiraan pendapatan Biogen BIIB|NBIX (Neurocrine) - Rega mangsa ngarep marang pendapatan|Regencell - Multiplikator Forward P/S|Rega forward marang dodolan AXSM (Axsome Corp)|XENE: Multiplikator Forward P/S|vikingtherapeutics.com (VKTX) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Supernus|CPRX: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Denali Therapeutics Inc (DNLI)|Multiplikator forward rega marang pendapatan Harmony Corp HRMY|Multiplikator Forward P/S BHVN (Biohaven Ltd.)|Multiplikator Forward P/S amylyx.com AMLX|Trevi Therapeutics, Inc. - Multiplikator Forward P/S|Praxis Precision Medicines Inc (PRAX) - Multiplikator forward rega marang pendapatan|AVXL: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep CeriBell EEG (CBLL)|Multiplikator forward rega marang pendapatan PRTA|Multiplikator Forward P/S Alector Therapeutics|Multiplikator forward rega marang pendapatan ANNX (Annexon)|Rasio rega marang pendapatan sing dikarepake OMER|Multiplikator Forward P/S NGNE (Neurogene Corp)|Rasio kapitalisasi marang dodolan sing dikarepake AC Immune Inc (ACIU)|Voyager Therapeutics - Multiplikator Forward P/S|neumoratx.com (NMRA) - Multiplikator forward rega marang pendapatan|SCLX: Multiplikator Forward P/S|Tevogen Bio Holdings Inc. (TVGN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Alpha Cognition Inc|Rasio rega marang prakiraan pendapatan CGTX|Rasio rega marang prakiraan pendapatan Inhibikase Therapeutics (IKT)|Rasio kapitalisasi marang dodolan sing dikarepake cassavasciences.com|Multiplikator Forward P/S ASRT (Assertio)|Multiplikator Forward P/S Coya Therapeutics Inc COYA|VistaGen Therapeutics Inc - Multiplikator Forward P/S|Ovid Therapeutics Inc. (OVID) - Multiplikator forward rega marang pendapatan|ABOS: Multiplikator Forward P/S|cervomed.com (CRVO) - Multiplikator Forward P/S|ATHE (Alterity Therapeutics Ltd.) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan CLNN (Clene Nanomedicine)|Rasio rega marang prakiraan pendapatan PepGen Inc. (PEPG)|Jupiter Neurosciences, Inc. - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S RLMD (Relmada Therapeutics)|annovisbio.com (ANVS) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|GRCE: Multiplikator forward rega marang pendapatan|AIFF - Multiplikator Forward P/S|anewmeds.com (KLTO) - Rasio rega marang prakiraan pendapatan|NeuroSense Therapeutics Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Reviva Pharmaceuticals|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep MetaVia, Inc. MTVA|Multiplikator Forward P/S NRXS|Multiplikator Forward P/S heliusmedical.com (HSDT)|Multiplikator Forward P/S PASG (Passage Bio)|NEUP - Multiplikator forward rega marang pendapatan|Minerva Neurosciences - Multiplikator Forward P/S|ATHA - Multiplikator Forward P/S|ADXN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ALZN|CYCN (Cyclerion Therapeutics Inc.) - Multiplikator Forward P/S|Protagenic (PTIX) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S KTTA|Multiplikator Forward P/S cortigent.com (CRGT)|Avenue Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan BCLI|CARA - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CHRO|ELYM: Multiplikator Forward P/S|Intra-Cellular Therapies, Inc. - Rega forward marang dodolan|LBPH (Longboard Pharmaceuticals, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Marinus Pharmaceuticals Inc|Rasio rega marang prakiraan pendapatan NKGen (NKGN)|NRBO (NeuroBo Pharma) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Sage Therapeutics, Inc. SAGE|SNPX - Multiplikator forward rega marang pendapatan|Trevena - Multiplikator Forward P/S|VIGL - Multiplikator Forward P/S|WENA: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Cerevel Corp
